Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring tailored clinical intervention.

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Medical oncologist Dr. Komal Jhaveri presented results from a clinical trial testing a drug known as an antibody-drug conjugate, which delivers a chemotherapy payload more precisely to breast cancer ...

Scanning electron microscope image showing pearl-like calcium granules (PCGs) accumulated within the lumen of the distal region of the Malpighian tubule in the fruit fly larva. Numerous PCGs, each ...

In today's hyper-connected world, cyber threats are more sophisticated and frequent than ever - ransomware attacks, data breaches, social engineering scams, and advanced persistent threats targeting ...

Exposure to endocrine-disrupting chemicals in early life, including during gestation and infancy, results in a higher preference for sugary and fatty foods later in life, according to an animal study ...

When these hormones become imbalanced, it can lead to the development of an endocrine disorder. “An endocrine disorder occurs when your body produces either too much or too little of a particular ...

Linux is the most flexible and customizable operating system on the planet. That customizability starts deep within the heart of the Linux kernel and the file system. A computer file system is a ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its ...

Women receiving endocrine therapy for hormone receptor (HR)–positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking on ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer. A 52-year-old postmenopausal woman with endocrine-refractory, ...